These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8632563)
1. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. Chirikos TN; Sanford E J Urol; 1996 Apr; 155(4):1311-6. PubMed ID: 8632563 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339 [TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of treatment strategies for benign prostatic hyperplasia--is medical therapy more costly in the long run? Saigal CS; Movassaghi M; Pace J; Joyce G; J Urol; 2007 Apr; 177(4):1463-7; discussion 1467. PubMed ID: 17382755 [TBL] [Abstract][Full Text] [Related]
4. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. Shah M; Butler M; Bramley T; Curtice TG; Fine S Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695 [TBL] [Abstract][Full Text] [Related]
5. Economic costs of benign prostatic hyperplasia in the private sector. Saigal CS; Joyce G J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787 [TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. McDonald H; Hux M; Brisson M; Bernard L; Nickel JC Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054 [TBL] [Abstract][Full Text] [Related]
8. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823 [TBL] [Abstract][Full Text] [Related]
9. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205 [TBL] [Abstract][Full Text] [Related]
10. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214 [TBL] [Abstract][Full Text] [Related]
11. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Black L; Naslund MJ; Gilbert TD; Davis EA; Ollendorf DA Am J Manag Care; 2006 Mar; 12(4 Suppl):S99-S110. PubMed ID: 16551208 [TBL] [Abstract][Full Text] [Related]
12. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. Souverein PC; van Riemsdijk MM; de la Rosette JJ; Opdam PC; Leufkens HG Eur Urol; 2005 Apr; 47(4):505-10. PubMed ID: 15774250 [TBL] [Abstract][Full Text] [Related]
13. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. Rosario DJ; Phillips JT; Chapple CR J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409 [TBL] [Abstract][Full Text] [Related]
14. Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms? Ragnarson Tennvall G; Hjelmgren J; Malmberg L Scand J Urol Nephrol; 2006; 40(6):495-505. PubMed ID: 17130102 [TBL] [Abstract][Full Text] [Related]
15. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Johansen TE; Istad JA Scand J Urol Nephrol; 2007; 41(2):124-31. PubMed ID: 17454951 [TBL] [Abstract][Full Text] [Related]
16. Incontinence related to management of benign prostatic hypertrophy. Han E; Black LK; Lavelle JP Am J Geriatr Pharmacother; 2007 Dec; 5(4):324-34. PubMed ID: 18179990 [TBL] [Abstract][Full Text] [Related]
17. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. Stovsky MD; Griffiths RI; Duff SB J Urol; 2006 Oct; 176(4 Pt 1):1500-6. PubMed ID: 16952668 [TBL] [Abstract][Full Text] [Related]
18. New insights into the epidemiology and natural history of benign prostatic hyperplasia. Boyle P Prog Clin Biol Res; 1994; 386():3-18. PubMed ID: 7528398 [TBL] [Abstract][Full Text] [Related]
19. Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Blomqvist P; Ekbom A; Carlsson P; Ahlstrand C; Johansson JE Urology; 1997 Aug; 50(2):214-9; discussion 219-20. PubMed ID: 9255291 [TBL] [Abstract][Full Text] [Related]